the hybridoma cell line h460 - 16 - 2 was deposited , in accordance with the budapest treaty , with the american type culture collection , 10801 university blvd ., manassas , va 20110 - 2209 on sept . 4 , 2002 , under accession number pta - 462 1 . in accordance with 37 cfr 1 . 808 , the depositors assure that all restrictions imposed on the availability to the public of the deposited materials will be irrevocably removed upon the granting of a patent . h460 - 16 - 2 monoclonal antibody was produced by culturing the hybridomas in cl - 11 1000 flasks ( bd biosciences , oakville , on ) with collections and reseeding occurring twice / week and was purified according to standard antibody purification procedures with protein g sepharose 4 fast flow ( amersham biosciences , baie d ′ urf { acute over ( e ,)} qc ). with reference to the data shown in fig1 and 2 , 4 to 8 week old , female scid mice were implanted with 5 million mb - 231 human breast cancer cells in 100 microliters saline injected subcutaneously in the scruff of the neck . the mice were randomly divided into 3 treatment groups of 10 . on the day prior to implantation 20 mg / kg of h460 - 16 - 2 test antibody , antibody buffer or isotype control antibody ( known not to bind mb - 231 cells ) was administered intrapertioneally at a volume of 300 microliters after dilution from the stock concentration with a diluent that contained 2 . 7 mm kcl , 1 mm kh 2 po 4 , 137 mm nacl and 20 mm na 2 hpo 4 . the antibodies were then administered once per week for a period of 7 weeks in the same fashion . tumor growth was measured roughly every 7th day with calipers for up to 10 weeks or until individual animals reached the canadian council for animal care ( ccac ) end - points or day 120 . body weights of the animals were recorded for the duration of the study . at the end of the study all animals were euthanised according to ccac guidelines . the data presented in this study is a typical example of a longitudinal data set . usually , in such data sets there are high correlations among time - points and higher correlations are observed between closer time - points . because of this , repeated measures analysis of variance ( rep . anova ) was used to determine the differences among treatments and the method of analysis of covariance was used to determine the time - points when differences occurred . the latter is a suitable method when the differences among groups at each time - point may not be just due to groups but may be due to the previous time - points . there were no clinical signs of toxicity throughout the study . body weight measured at weekly intervals was a surrogate for well - being and failure to thrive . fig1 represents the mean body weight of mice for the 3 groups over the study period . body weights within each group increased over time . rep . anova indicated that there was no significant difference among groups and the mean profiles do not differ over time - points for the groups treated with isotype control , antibody buffer or h460 −- 16 - 2 . using rep . anova for the whole experiment , the following results were noticeable . the rep . anova method indicated that not only the means of the groups were different ( p & lt ; 0 . 001 ) but also the shapes of the mean profiles differed from each other . as can be seen in fig2 treatment group h460 - 16 - 2 seemed to have a superior effect compared to the other groups . in addition , the difference between the isotype control treated group and the antibody buffer treated group was not statistically significant . from analysis of covariance , significant differences occurred for the first time at day 18 , where isotype and buffer treatment groups differed from the h460 - 16 - 2 treatment group . at day 53 , ( the first tumor volume measurement after the cessation of treatment ) tumor volume of the group treated with h460 - 6 16 - 2 was 1 . 3 % of the antibody control treated group ( p & lt ; 0 . 0001 ) thereby demonstrating effectiveness at preventing tumor burden . there was also a corresponding survival benefit ( fig3 ) from treatment with h460 - 16 - 2 . enhanced survival is a valuable indicator of efficacy . all 3 groups were followed for over 70 days post - treatment . the cox proportional hazard test estimates that the risk of dying in in arh460 - 16 - 2 group was about 71 % of the buffer control group ( p = 0 . 028 ). these data demonstrate that treatment with the test antibody confers a survival benefit compared to control - treated groups . control groups reached 50 % mortality between day 74 - 81 post - implantation . in contrast , treated groups had not reached 50 % mortality at the time of termination of the study ( day 120 post - implantation ). the isotype control group treatment group reached 100 % mortality by day 74 post - implantation . in contrast , h460 - 16 - 2 treated animals displayed 60 % survival at the end of the study . in summary , h460 - 16 - 2 antibody treatment prevented tumor burden and increased survival in comparison to a control antibody in a well - recognized model of human cancer disease . these results suggest a potential pharmacologic and pharmaceutical benefit of this antibody ( h460 - 16 - 2 ) as a therapy in other mammals , including man . female scid mice , 5 to 6 weeks old , were implanted with 5 million mb - 231 breast cancer cells in 100 microliters saline injected subcutaneously in the scruff of the neck . tumor growth was measured with calipers every week . when the majority of the cohort reached a tumor volume of 100 mm 3 ( range 70 - 130 mm 3 ) at 34 days post implantation , 12 mice were randomized into each of four treatment groups . h460 - 16 - 2 or isotype control antibody ( known not to bind mb - 231 cells ) was administered intravenously with 15 mg / kg / dose at a volume of 150 microliters after dilution from the stock concentration with a diluent that contained 2 . 7 mm kcl , 1 mm kh 2 po 4 , 137 mm nacl and 20 mm na 2 hpo 4 ; cisplatin was administered at 9 mg / kg / dose ( diluted in saline ) intraperitoneally in 300 microliters . the antibodies were then administered 3 times per week for a total of 10 doses in the same fashion until day 48 post - implantation . cisplatin was administered every four days for 3 doses . tumor growth was measured around every 7th day with calipers for the duration of the study or until individual animals reached ccac end - points . body weights of the animals were recorded for the duration of the study . at the end of the study all animals were euthanised according to ccac guidelines . at the time of randomization the mean tumor volumes and the standard deviations in each group were similar : isotype control , ( 97 . 60 +/− 18 . 33 ); h460 - 16 - 2 ( 95 . 25 +/- 16 . 82 ); cisplatin ( 98 . 00 +/− 18 . 93 ). this indicated that true randomization had occurred . as shown in fig4 the antibody h460 - 16 - 2 was able to significantly suppress tumor growth at the end of the 3 - week treatment period . comparisons of the mean tumor volume between the 3 groups showed the differences between the groups were highly significant ( table 1 ). further evaluation of efficacy was assessed by calculating t / c ( median tumor volume of treated ( t ) versus the median tumor volume of isotype control ( c ) in a percent ) ratios which reflect growth inhibition . h460 - 16 - 2 antibody achieved an endpoint of median t / c tumor volume equal to 49 % ( fig5 ). fig4 further shows that h460 - 16 - 2 treatment resulted in marked suppression of tumor growth when compared to the isotype control and that the suppression was { fraction ( 2 / 3 )} that of cisplatin given at its maximum tolerated dose ( mtd ) but without cisplatin &# 39 ; s accompanying toxicity or death . body weights recorded weekly for the duration of the experiment were used as a surrogate for evaluation of safety and toxicity . as outlined in table 2 and displayed in fig6 there was a minimal difference in weight for the groups treated with the isotype control or h460 - 16 - 2 . in contrast , during the treatment period , there was significant ( p = 0 . 0005 ) cachexia observed in the cisplatin group . in this group , weight loss reached 19 . 2 % of the initial body weight and additional evidence of clinical distress such as ruffled fur , skin tenting due to dehydration and lethargy occurred . there were no deaths in the h460 - 16 - 2 treated group compared to 2 deaths observed in the cisplatin treated group . h460 - 16 - 2 showed a survival benefit in comparison to treatment with isotype control ( fig7 ). by day 170 ( around 120 days post - treatment ), 33 percent of the h460 - 16 - 2 treatment group was still alive compared to 0 percent for both the cisplatin and isotype control groups . in summary , h460 - 16 - 2 is significantly more effective than the isotype control antibody in suppressing tumor growth in an established tumor xenograft model of breast cancer in scid mice . over the 3 - week treatment period , h460 - 16 - 2 achieved an endpoint of median t / c tumor volumes of less than 50 % relative to control . in addition , h460 - 16 - 2 resulted in suppression that was two thirds that of cisplatin given at mtd but without the signs of toxicity or death observed with the chemotherapeutic drug . therefore treatment with h460 - 16 - 2 significantly decreased the tumor burden of established tumors in comparison to a control antibody and showed survival benefits in a well - recognized model of human cancer disease suggesting pharmacologic and pharmaceutical benefits of this antibody for therapy in other mammals , including man . the distribution of the h460 - 16 - 2 antigen was studied in mouse tissues and compared to the gp96 antigen . ihc optimization studies were initially performed in order to determine the conditions for further experiments . h460 - 16 - 2 monoclonal antibody was produced and purified as stated above . an untreated mouse implanted sub - cutaneously with mb - 231 tumor cells was euthanised 74 days post - implantation . tumor tissue and tissue from major organs were dissected out and fixed in 10 % neutral buffered formalin for 48 hours . following fixation , the tissues were transferred to 70 % ethanol , processed , paraffin - embedded , sectioned and mounted on glass slides for staining . slides were deparaffinized by drying in an oven at 60 ° c for 1 hour and dewaxed by immersing in xylene 5 times for 4 minutes each in coplin jars . following treatment through a series of graded ethanol washes ( 100 %- 75 %) the sections were re - hydrated in water . the slides were immersed in 10 mm citrate buffer at ph 6 ( dako , toronto , on ) then microwaved at high , medium , and low power settings for 5 minutes each and finally immersed in cold pbs . slides were then immersed in 3 % hydrogen peroxide solution for 6 minutes , washed with pbs three times for 5 minutes each , dried , incubated with universal blocking solution ( dako , toronto , on ) for 5 minutes at room temperature , and dried . h460 - 16 - 2 , monoclonal mouse anti - vimentin ( dako , toronto , on ) and anti - grp94 , also known as anti - gp96 , ( stressgen biotechnologies , victoria , bc ) were diluted in antibody dilution buffer ( dako , toronto , on ) to its working concentration ( either 2 . 5μg / ml , 5μg / ml or 10μg / ml for each antibody ) and incubated overnight in a humidified chamber at 4 ° c . the slides were washed with pbs 3 times for 5 minutes each . immunoreactivity of the primary antibodies was detected / visualized with hrp conjugated secondary antibodies as supplied ( dako envision system , toronto , on ) for 30 minutes at room temperature . following this step the slides were washed with pbs 3 times for 5 minutes each and a color reaction developed by adding dab ( 3 , 3 ′- diaminobenzidine tetrahydrachloride , dako , toronto , on ) chromogen substrate solution for immunoperoxidase staining for 10 minutes at room temperature . washing the slides in tap water terminated the chromogenic reaction . following counterstaining with meyer &# 39 ; s hematoxylin ( sigma diagnostics , oakville , on ), the slides were dehyrdated with graded ethanols ( 75 - 1 00 %) and cleared with xylene . using mounting media ( dako faramount , toronto , on ) the slides were coverslipped . slides were microscopically examined using an axiovert 200 ( zeiss canada , toronto , on ) and digital images acquired and stored using northern eclipse imaging software ( mississauga , on ). results were read , scored and interpreted by a pathologist . the optimum concentration was the one that produced the expected results for the positive ( anti - gp96 ) and negative control antibodies ( anti - vimentin ). the anti - vimentin antibody has been shown to be negative on mouse tissue but positive on human tissue . the anti - gp96 antibody has previously been shown to be positive on both mouse and human tissue . in these studies both the high and low concentrations did not produce the expected results with the control antibodies , but the 5 μg / ml concentration did . the results of an ihc survey of scid mouse tissue and engrafted human breast cancer , mb - 231 ( table 3 ) shows the negative control antibody anti - vimentin is negative for mouse tissue but positive for human tissue . anti - vimentin ( fig8 a ) shows intense cytoplasmic and some membranous staining ; h460 - 16 - 2 shows intense membranous staining ( fig8 b ), and anti - gp96 shows occasional positive punctate and cytoplasmic staining cells ( fig8 c ). anti - vimentin ( fig9 a ) and h460 - 16 - 2 ( fig9 b ) did not stain mouse liver but anti - gp96 produced intense cytoplasmic staining of hepatocytes ( fig9 c ). anti - vimentin ( fig1 a ) did not stain mouse kidney . h460 - 16 - 2 ( fig1 b ) showed apical staining of the proximal and distal convoluted tubules while anti - gp96 produced diffuse staining of the same cells with a cytoplasmic and punctate pattern ( fig1 c ). anti - vimentin ( fig1 a ) did not stain mouse ovary . h460 - 16 - 2 ( fig1 b ) showed cytoplasmic and nuclear staining of only the ova while anti - gp96 produced diffuse cytoplasmic and nuclear staining of the ova and cytoplasmic and punctate staining of granulosa cells ( fig1 c ). the anti - vimentin negative control antibody gave the expected staining of human tissues and lack of staining of mouse tissues ( see fig8 - 11 ). the anti - gp96 antibody was used as a positive control because of the likelihood that the h460 - 16 - 2 antigen is a cancer variant of gp96 . the anti - gp96 antibody did show staining of mb - 231 cells ( fig8 ) which is consistent with the association of gp96 expression with breast cancer . gp96 was also expressed in the cytoplasm of many cell types involved with protein synthesis such as hepatocytes , cells of the islets of langerhans in the pancreas , ovarian granulosa cells and the ova , and mucosal epithelium in the fallopian tubes ( table 3 ). this is entirely consistent with the putative role for gp96 as an endoplasmic reticular chaperone protein . h460 - 16 - 2 antibody stained mb - 231 cells which is consistent with its in vivo effects in the corresponding tumor model . in addition it stained the dct and pct in the mouse kidney ( table 3 ) as well as the mouse ova ( fig1 ). from this sampling of mouse tissues it would appear that the h460 - 16 - 2 antigen is not restricted to just human cells but is also expressed in the mouse in such a way that the antibody can recognize the antigen . significantly there are differences in the expression of the h460 - 16 - 2 and gp96 antigen as demonstrated with the staining of normal mouse kidney tissue ; apical staining was obtained with h460 - 16 - 2 while diffuse staining was seen with anti - gp96 ( fig1 ). another example of this is the additional staining of the ova with anti - gp96 ( fig1 ). a key difference is that h460 - 16 - 2 staining does not occur in the liver , while gp96 staining is quite extensive ( fig9 ). in order to further the experiments described above , h460 - 16 - 2 , anti - gp96 ( for comparison to h460 - 16 - 2 ) and anti - vimentin ( negative control ) was used to stain a normal mouse tissue array ( imgenex , san diego , ca ). the staining procedure used was the same as stated above . as summarized in table 4 , anti - vimentin did not stain any of the tissues tested ; h460 - 16 - 2 again stained only the ovary and kidney while anti - gp96 continued to stain a much broader range of mouse tissues . these results are consistent with those stated above and again demonstrates that h460 - 16 - 2 expression is not limited to human cells and that its expression is restricted and specific on normal mouse tissue . it also confirms that h460 - 16 - 2 stains the same tissues as anti - gp96 but anti - gp96 continued to stain a much broader range of tissues supporting the idea that the h460 - 16 - 2 antigen may be a subset of gp96 . ihc studies were conducted to characterize h460 - 16 - 2 antigen distribution in humans . it was compared to an antibody directed against gp96 since the h460 - 16 - 2 antigen may be a cancer variant of gp96 as determined previously by biochemical methods . binding of antibodies to 60 normal human tissues was performed using a human , normal organ tissue array ( imgenex , san diego , ca ). all primary antibodies ( h460 - 16 - 2 ; anti - grp94 ( also known as anti - gp96 , stressgen biotechnologies , victoria , bc ); and mouse iggi negative control ( dako , toronto , on )) were diluted in antibody dilution buffer ( dako , toronto , on ) to a concentration of 5 μg / ml ( found to be the optimal concentration in optimization steps ). the negative control antibody has been shown to be negative to all mammalian tissues by the manufacturer . the procedure for ihc from example 3 was followed . table 5 presents a summary of the results of h460 - 16 - 2 staining to an array of normal human tissues . from the table , there are three categories of tissue staining . a group of tissues was completely negative . these tissues included normal heart , kidney , brain , pancreas , breast , testis , ovary and placenta . a second group of tissues comprised tissues that demonstrated positive staining . these included the skin , ureter , stomach and prostate . the salivary gland demonstrated the strongest staining with this antibody . a third group of tissues included tissues in which staining was positive in the tissue section , but was limited to infiltrating macrophages , lymphocytes and fibroblasts . this included macrophages in the lung , liver , stomach , intestine and colon , as well as lymphocytes in the spleen and gall bladder . it should be noted that the antigen is not present on cells in the vital organs , including liver , kidney , heart and lung . the antibody does bind to macrophages and lymphocytes , and their presence is observed in some of the organs in these sections . in comparison , tissues that were negative for anti - gp96 included subcutaneous fat , skeletal muscle , lung , heart , stomach smooth muscle , urinary bladder , myometrium , ovary , placental cord , brain ( white and gray matter ), cerebellum , and spinal cord . with the exception of the myometrium , all of these tissues were also negative for h460 - 16 - 2 staining . these results suggest that h460 - 16 - 2 binds to a smaller subset of the tissues recognized by the anti - gp96 antibody . this is consistent with the mouse tissue study , in which anti - gp96 bound to liver , pancreas , brain and fallopian tubes in addition to the two tissues that were also bound by h460 - 16 - 2 , kidney and ovary . these results suggest that the antigen for h460 - 16 - 2 is not widely expressed on normal tissues , and that the antibody would bind specifically to a limited number of tissues in humans . to delineate the differences between the distribution of gp96 and the h460 - 16 - 2 antigen , the cell types where the antigens are expressed were tabulated in table 6 . from the table , it is clear that the anti - gp96 antibody binds to a wider range of cell types than h460 - 16 - 2 . further , the strongest binding of h460 - 16 - 2 was to fibroblasts , acinar epithelium , and lymphocytes . there was weak binding to macrophages , keratinocytes , smooth muscle , mucosal epithelium , and thyroid follicular cells . anti - gp96 bound to an additional 15 cell types , and to each cell type that expressed the h460 - 16 - 2 antigen . this suggests that the h460 - 16 - 2 antigen is a subset of gp96 since there were no cells that expressed h460 - 16 - 2 that did not express the gp96 antigen . these tissue surveys demonstrated that the h460 - 16 - 2 antigen has a very limited distribution in normal tissues including the vital organs . the experiment also showed that the anti - gp96 antibody bound to a wider range of tissues compared to h460 - 16 - 2 . h460 - 16 - 2 binds to a subset of the tissues bound by anti - gp96 and to limited cell types . in the tissues that were h460 - 16 - 2 positive but not gp96 positive , h460 - 16 - 2 bound to only macrophages and fibroblasts , cell types which generally expressed gp96 . the difference between the mouse and human tissue surveys also point out that the h460 - 16 - 2 antibody recognizes an antigen that is relevant in humans and of limited importance in normal mice since the expression is so limited . the h460 - 16 - 2 antibody itself is applicable in humans since it does recognize the human form of the antigen . an ihc study was undertaken to determine the cancer association of the h460 - 16 - 2 antigen with human breast cancers and whether the h460 - 16 - 2 antibody was likely to recognize human cancers . a comparison was made for anti - gp96 staining , and an antibody directed towards aspergillus niger glucose oxidase , an enzyme which is neither present nor inducible in mammalian tissues ( negative control ). a breast cancer tissue array derived from 50 breast cancer patients and 9 samples derived from non - neoplastic breast tissue in breast cancer patients was used ( imgenex corporation , san diego , ca ). the following information was provided for each patient : age , sex , american joint committee on cancer ( ajcc ) tumor stage , lymph node , estrogen receptor ( er ) and projesterone receptor ( pr ) status . the procedure for ihc from example 3 was followed . all antibodies were used at a working concentration of 5 μg / ml . tables 7 and 8 provide binding summaries of h460 - 16 - 2 and anti - gp96 antibody to a breast cancer tissue array respectively . each array contained tumor samples from 50 individual patients . overall , 64 percent of the 50 patients tested were positive for h460 - 16 - 2 antigen compared to 84 percent for gp96 . for both the h460 - 16 - 2 and gp96 antigen , only 2 out of normal breast tissue samples from breast cancer patients were positive . no clear correlation between estrogen and progesterone receptor status was evident . it also appeared there was a trend to greater positive expression of the h460 - 16 - 2 antigen with higher tumor stage . the h460 - 16 - 2 staining was quite specific for cancerous cells over normal cells as demonstrated in fig1 where stromal cells were clearly negative and sheets of malignant cells were highly positive . the cellular localization pattern seen with the h460 - 16 - 2 antigen was confined to the cell membrane in the majority of cases . the anti - gp96 antibody stained more breast cancer samples but consistently showed membrane as well as substantial cytoplasmic localization ( fig1 ). anti - gp96 stained the same samples of normal tissue from breast cancer patients as h460 - 16 - 2 . these results suggest the antigen for h460 - 16 - 2 may be expressed by almost two thirds of breast cancer patients . the staining pattern showed that in patient samples , the antibody is highly specific for malignant cells and the h460 - 16 - 2 antigen is localized to the cell membrane thereby making it an attractive druggable target . [ 0090 ] table 8 ihc with anti - gp96 on human breast normal and tumor anti - gp96 total # − +/− + ++ +++ total positive % positive patient tumor 50 8 9 12 9 12 42 84 samples normal 9 7 0 1 1 0 2 22 er er + 21 6 5 4 3 3 15 71 status er − 28 1 4 8 6 9 27 96 unknown 1 1 0 0 0 0 0 0 pr pr + 11 4 1 2 2 2 7 64 status pr − 38 3 8 10 7 10 35 92 unknown 1 1 0 0 0 0 0 0 ajcc t1 7 2 2 0 3 0 5 71 tumor t2 26 5 5 5 5 6 21 81 stage t3 16 1 2 6 1 6 15 94 t4 1 0 0 1 0 0 1 100 to determine whether the h460 - 16 - 2 antigen is expressed on other human tumor tissues besides breast , h460 - 16 - 2 was used on a multiple human tumor tissue array ( ihgenex , san diego , ca ). the following information was provided for each patient : age , sex , organ and diagnosis . the staining procedure used was the same as the one outlined in example 3 . vimentin was used as a positive control antibody and the same negative control antibody was used as described for the human breast tumor tissue array . all antibodies were used at a working concentration of 5 [ g / ml . as outlined in table 9 , h460 - 16 - 2 stained a number of various human cancers besides breast . the following tumor types were always positive for h460 - 16 - 2 ( albeit to different degrees ): lymph node ({ fraction ( 2 / 2 )}), bone ({ fraction ( 2 / 2 )}), lung ({ fraction ( 4 / 4 )}), kidney ({ fraction ( 3 / 3 )}), uterus ({ fraction ( 3 / 3 )}), and thyroid ({ fraction ( 2 / 2 )}). the stomach ({ fraction ( 4 / 5 )}), liver ({ fraction ( 2 / 3 )}) and partied gland ({ fraction ( 2 / 3 )}) also showed up relatively consistently positive for staining . several other tumor types also occasionally stained positive . as seen with the breast cancers , h460 - 16 - 2 staining was localized predominately on the membrane of cancerous cells . therefore , it appears that the h460 - 16 - 2 antigen is not solely found on the membranes of breast cancers but also on the membrane of a large variety of tumor types . these results indicate that h460 - 16 - 2 has potential as a therapeutic drug in a wide variety of tumor types besides breast . all patents and publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains . all patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference . it is to be understood that while a certain form of the invention is illustrated , it is not to be limited to the specific form or arrangement of parts herein described and shown . it will be apparent to those skilled in the art that various changes may be made without departing from the scope of the invention and the invention is not to be considered limited to what is shown and described in the specification . one skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned , as well as those inherent therein . any oligonucleotides , peptides , polypeptides , biologically related compounds , methods , procedures and techniques described herein are presently representative of the preferred embodiments , are intended to be exemplary and are not intended as limitations on the scope . changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention and are defined by the scope of the appended claims . although the invention has been described in connection with specific preferred embodiments , it should be understood that the invention as claimed should not be unduly limited to such specific embodiments . indeed , various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art are intended to be within the scope of the following claims .
the present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening . by segregating the anti - cancer antibodies using cancer cell cytotoxicity as an end point , the process makes possible the production of anti - cancer antibodies for therapeutic and diagnostic purposes . the antibodies can be used in aid of staging and diagnosis of a cancer , and can be used to treat primary tumors and tumor metastases . the anti - cancer antibodies can be conjugated to toxins , enzymes , radioactive compounds , and hematogenous cells .